Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

RXi Pharmaceuticals, UMMS collaborate on ocular disease
February 2010
SHARING OPTIONS:

WORCESTER, Mass.RXi Pharmaceuticals Corp., a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced in January a collaboration with Dr. Shalesh Kaushal, chairman of the Department of Ophthalmology at the University of Massachusetts Medical School. The research collaboration will be focused on the application of RXi's self-delivering RNAi (sd-rxRNA) compounds for ocular diseases such as age-related macular degeneration, the leading cause of blindness in Americans over 55 years of age. RXi previously presented encouraging data on spontaneous cellular uptake and potent activity of sd-rxRNA compounds in retinal cells. Financial terms of the collaboration were not released.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.